Advertisement

Crebbp loss cooperates with Bcl2 over-expression to promote lymphoma in mice

Idoia García-Ramírez, Saber Tadros, Inés González-Herrero, Alberto Martín-Lorenzo, Guillermo Rodríguez-Hernández, Dalia Moore, Lucía Ruiz-Roca, Oscar Blanco, Diego Alonso-López, Javier De Las Rivas, Keenan Hartert, Romain Duval, David Klinkebiel, Martin Bast, Julie Vose, Matthew Lunning, Kai Fu, Timothy Greiner, Fernando Rodrigues-Lima, Rafael Jiménez, Francisco Javier García Criado, María Begoña García Cenador, Paul Brindle, Carolina Vicente-Dueñas, Ash Alizadeh, Isidro Sánchez-García and Michael R. Green

Key points

  • Crebbp inactivation perturbs B-cell development, but cooperates with Bcl2 over-expression to promote lymphoma.

  • Transcriptional and epigenetic signatures of Crebbp loss implicate Myc in disease etiology.

Abstract

CREBBP is targeted by inactivating mutations in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). Here, we provide evidence from transgenic mouse models that Crebbp deletion results in deficits in B-cell development and can cooperate with Bcl2 over-expression to promote B-cell lymphoma. Through transcriptional and epigenetic profiling of these B-cells we found that Crebbp inactivation was associated with broad transcriptional alterations, but no changes in the patterns of histone acetylation at the proximal regulatory regions of these genes. However, B-cells with Crebbp inactivation showed high expression of Myc and patterns of altered histone acetylation that were localized to intragenic regions, enriched for Myc DNA binding motifs, and showed Myc binding. Through the analysis of CREBBP mutations from a large cohort of primary human FL and DLBCL, we show a significant difference in the spectrum of CREBBP mutations in these two diseases, with higher frequencies of nonsense/frameshift mutations in DLBCL compared to FL. Together our data therefore provide important links between Crebbp inactivation and Bcl2 dependence, and show a role for Crebbp inactivation in the induction of Myc expression. We suggest this may parallel the role of CREBBP frameshift/nonsense mutations in DLBCL that result in loss of the protein, but may contrast the role of missense mutations in the lysine acetyltransferase domain that are more frequently observed in FL and yield an inactive protein.

  • Submitted August 11, 2016.
  • Accepted March 5, 2017.